- Home
- ENTX vs IMAB Comparison
ENTX vs IMAB Comparison
Compare ENTX & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- IMAB
- Stock Information
- Founded
- ENTX 2010
- IMAB 2014
- Country
- ENTX Israel
- IMAB United States
- Employees
- ENTX N/A
- IMAB N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- IMAB Health Care
- Exchange
- ENTX Nasdaq
- IMAB Nasdaq
- Market Cap
- ENTX 104.0M
- IMAB 200.9M
- IPO Year
- ENTX 2018
- IMAB 2020
- Fundamental
- Price
- ENTX N/A
- IMAB $2.16
- Analyst Decision
- ENTX Strong Buy
- IMAB Strong Buy
- Analyst Count
- ENTX 1
- IMAB 2
- Target Price
- ENTX $10.00
- IMAB $6.00
- AVG Volume (30 Days)
- ENTX 33.0K
- IMAB 982.8K
- Earning Date
- ENTX 08-08-2025
- IMAB 05-15-2025
- Dividend Yield
- ENTX N/A
- IMAB N/A
- EPS Growth
- ENTX N/A
- IMAB N/A
- EPS
- ENTX N/A
- IMAB N/A
- Revenue
- ENTX $223,000.00
- IMAB N/A
- Revenue This Year
- ENTX N/A
- IMAB N/A
- Revenue Next Year
- ENTX N/A
- IMAB N/A
- P/E Ratio
- ENTX N/A
- IMAB N/A
- Revenue Growth
- ENTX N/A
- IMAB N/A
- 52 Week Low
- ENTX $1.41
- IMAB $0.60
- 52 Week High
- ENTX $2.79
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- ENTX 43.51
- IMAB 50.70
- Support Level
- ENTX $1.84
- IMAB $2.00
- Resistance Level
- ENTX $2.02
- IMAB $2.95
- Average True Range (ATR)
- ENTX 0.14
- IMAB 0.34
- MACD
- ENTX -0.01
- IMAB -0.08
- Stochastic Oscillator
- ENTX 14.71
- IMAB 15.79
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).